Pacira Pharm Inc (PCRX) 36.49 $PCRX Technical Analysis

New Post Public Reply Private Reply Replies (0) Message Board

Jul 12, 2016 at 3:15 AM

Pacira Pharm Inc (PCRX) 36.49 $PCRX

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.22 (-0.15), CPRX: 0.80 (unch), AKRX: 30.91 (+0.25), PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2016 Healthcare Conference at 9 a.m. ET on Tuesday, June 7, 2016, in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Tue May 03, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company.
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained
Sean Williams, The Motley Fool - Motley Fool - Mon May 02, 3:02PM CDT
Image source: NIH Image Gallery via Flickr. What: Shares of Pacira Pharmaceuticals , a specialty pharmaceutical company primarily focused on the development of medicines to help in the acute hospital care setting, dipped by as much as 10%...
PCRX: 36.49 (+0.10)

Pacira reports 1Q loss
Automated Insights - Mon May 02, 6:40AM CDT
PARSIPPANY, N.J. (AP) _ Pacira Pharmaceuticals Inc. (PCRX) on Monday reported a first-quarter loss of $3.9 million, after reporting a profit in the same period a year earlier.
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 6:34AM CDT
-- Total Net Revenues Up 12 Percent Year-Over-Year --
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals Appoints Charles A. Reinhart, III, as Chief Financial Officer
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced the appointment of Charles A. Reinhart, III, to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently President, and will report to Dave Stack, Chief Executive Officer and Chairman. Mr. Reinhart will start in this new role effective Tuesday, May 3, 2016.
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals (PCRX) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 7:48AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) has moved higher as of late, but there could definitely be trouble on the horizon for this company
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
GlobeNewswire - Thu Apr 14, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that financial results for the company's first quarter ended March 31, 2016 will be released before the market opens on Monday, May 2, 2016. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Monday, May 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 54803652.
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr. Weiland will be responsible for oversight of the commercial activities for EXPAREL (bupivacaine liposome injectable suspension), which include marketing, sales, national accounts, training and commercial operations and analytics. Mr. Weiland will report to Jim Scibetta, President and Chief Financial Officer.
PCRX: 36.49 (+0.10)

Pacira (PCRX): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 9:05AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
PCRX: 36.49 (+0.10)

PixarBio's NeuroRelease(TM) A Revolutionary Non Addictive Pain Treatment Draws Pain Industry Star Sales Executive David Kaplan as Global VP of Sales & Marketing
BusinessWire - Wed Mar 09, 5:00AM CST
PixarBio Corporation inventors of NeuroRelease, a 14 day non-addictive post-surgical pain treatment with expected FDA approval in 2018, announced today the appointment of David Kaplan as Vice President of Global Sales and Marketing.
PCRX: 36.49 (+0.10)

Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 6:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company.
PCRX: 36.49 (+0.10)

CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 3:04PM CST
CTI BioPharma Corp. (CTIC) announced that the FDA has placed the company's Investigational New Drug (IND) application for pacritinib on a full clinical hold.
GILD: 86.25 (-0.30), MYL: 44.55 (+0.01), CTIC: 0.36 (+0.01), PCRX: 36.49 (+0.10)

Catalyst (CPRX) Initiates Study on Firdapse for MuSK-MG
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:25PM CST
Catalyst Pharmaceuticals, Inc. (CPRX) announced the initiation of a well-controlled study evaluating the efficacy, safety and tolerability of Firdapse for the treatment of MuSK-MG.
EARS: 4.03 (-0.06), CPRX: 0.80 (unch), CORT: 6.02 (+0.01), PCRX: 36.49 (+0.10)

Shire's NDA Resubmission for Lifitegrast Accepted by FDA
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 3:15PM CST
Shire plc (SHPG) announced that the FDA has acknowledged the receipt of the company's New Drug Application (NDA) for its pipeline candidate, lifitegrast.
AGN: 238.28 (-2.31), SHPG: 186.31 (-1.90), CORT: 6.02 (+0.01), PCRX: 36.49 (+0.10)

Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.21 (+0.02), CORT: 6.02 (+0.01), PCRX: 36.49 (+0.10), BIOD: 0.31 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carrier Drops $600M on U.S. Manufacturing Boost

A Mighty Move in Manufacturing Carrier Global Corporation's recent muscle-flexing is something rarer than a golden goose in today's market—a $600 million thrust into beefing up U.S. manufacturing and engineering. You can't help but wonder if this is overzealous optimism or a meticulously calculated power play. Clocks don't tick this loudly without good reason, of...

Asia-Pacific Travel Boom Spurs Growth in Emerging Cities

The Rise of Emerging Destinations in Asia-Pacific You could say the kids are driving the show this autumn, with Gen Z leading the charge in the Asia-Pacific travel boom. A surge in bookings across emerging destinations is shaking things up, and the scene feels fresh as a cold autumn breeze. We're seeing some stunning numbers—Chiang Mai up by a whopping 84.3%, followed...

Mixed Wage Growth: Gains for Some, Challenges Persist

A Closer Look at Q3 Earnings I tell you, these numbers from the Ludwig Institute make for a pretty mixed bag. Sure, we got a slight nudge upwards in those median weekly earnings for the third quarter, like from $1,035 to $1,041. It’s a pinch of positive news, but hang on a sec before you start celebrating. The reality ain't shifting for a lot of folks, especially if...

Forge Fest: A Peek into iAutomation's Tech Arsenal

Getting Down to Brass Tacks at Forge Fest If you're in Franklin, Massachusetts, on November 5, you might want to drop by iAutomation’s "Forge Fest"—no marketing fluff here, just pure, unadulterated exposure to cutting-edge automation tech. From technical presentations to hands-on demos, this event is serving an open buffet of innovation from big names in the...

Granite Gives Pink Raises $583K for Cancer Research

Not Just About Numbers: Employee-Led Push for Health If you've ever doubted the power of collective purpose, take a look at Granite Telecommunications' recent endeavor. This hard-hitting telecom giant, with its robust footprint across North America's communication and tech sectors, isn't resting on its laurels when it comes to social responsibility. Their 'Granite Gives...

TruGolf's E6 Golf Platform Hits 15,000 Courses Milestone

E6's Expanding Universe of Courses TruGolf's E6 is swinging big with a library that's breaking records—more than 15,000 real-world golf courses now available on demand. It's a leap of 50% in under a year, an impressive stride for any tech-driven platform, golfing or otherwise. The magic behind this growth? On-demand generation, allowing the software's library to expand...

Roofr Unveils AI Tools: Shaping Roofing's Future

Making Waves in Roofing: Roofr's Big Moves Listen up, folks. When a company like Roofr announces new tech, contractors better pay attention. The roofing industry—often overlooked by the flashy tech scene—just got hit with some slick new tools. Today, Roofr held its semi-annual virtual event, Roofr Builds, unraveling a slew of updates that might just streamline the way...

Ford Foundation's New Strategy Tackles Global Democracy

New Directions in a Changing World Standing at a crossroads of geopolitical upheaval and global uncertainty, the Ford Foundation is shaking things up with a fresh playbook aimed squarely at bolstering democracy across the globe. On October 22, 2026, they rolled out a game plan that's all about reinforcing the backbone of democratic values, essential freedoms, and...

Denver Arts Week: A Cultural Extravaganza Returns

Denver's got its art game on again, folks—a sprawling fiesta for the senses called Denver Arts Week is making its return from November 6 to 15. Pack your bags, grab a parka, or whatever you need to brace the Colorado chill, as this ain't just any regular art crawl—it's a full-blown celebration with nearly 300 events jam-packed across the city. If you blink, Denver...

Shareholder Deals Under Fire: PRTH, BWIN, CCC Scrutiny

When Deals Leave Shareholders in the Lurch Here's the deal, folks—three companies are under scrutiny for transactions that might leave their shareholders dry while insiders make a pretty penny. Priority Technology Holdings, Inc. (NASDAQ:PRTH), Baldwin Group, Inc. (NASDAQ:BWIN), and CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC) are being probed by Halper Sadeh LLC...